#United States #Puerto Rico #Amgen #Thousand Oaks #Biomanufacturing

Amgen's Manufacturing Investment Overview

Amgen, a leader in biotechnology, has unveiled its plan to invest an additional $300 million into its U.S. manufacturing network. This investment seeks to bolster production capacity, enhance next-generation technology, and ensure a reliable supply of medication for patients in need. This strategic move reflects Amgen’s continuous support and commitment to American manufacturing, a sentiment echoed by the company’s Chairman and CEO, Robert A. Bradway.

The Significance of the Investment

This investment marks a significant chapter in Amgen's history of U.S. biomanufacturing, which has spanned multiple decades. It's particularly focused on expanding operations in Puerto Rico, where Amgen has established a prominent manufacturing facility. The enhancement at the Juncos site—one of the world’s largest and most advanced biomanufacturing facilities—aims not only to boost production but also to generate numerous construction jobs and strengthen the local economy. The facility has been operational since 1992 and plays a crucial role in producing biologic medicines that are distributed to over 60 countries.

In the past year alone, Amgen has pledged $650 million in Puerto Rico, and $900 million in Ohio, along with a further $600 million for a science and innovation center in California, making the $300 million announcement part of a broader commitment to U.S. manufacturing.

Supporting Local Economies

The Puerto Rican Governor, Jenniffer González Colón, emphasized the importance of these investments, stating that they signal Puerto Rico’s long-standing dedication to the biopharmaceutical sector. Governor Colón highlighted, “Puerto Rico has more than 60 years of excellence in this field, backed by a skilled workforce and top-notch infrastructure.”

Moreover, it has been asserted that this expansion is a testament to Amgen’s trust in both the capabilities and the robust workforce available in Puerto Rico. The Department of Economic Development and Commerce of Puerto Rico has recognized this investment as a reflection of their pro-business initiatives, allowing world-class companies like Amgen to flourish.

A History of Commitment to Innovation

Amgen’s proactive stance in investing exceeds $40 billion since the Tax Cuts and Jobs Act (TCJA) of 2017 was enacted. The company attributes its ability to innovate and invest in domestic science and manufacturing to the favorable tax policies established under this act and reinforced by subsequent legislation, including the One Big Beautiful Bill Act of 2025.

Amgen's Role in Biotechnology

For over 45 years, Amgen has been pivotal in shaping the biotechnology industry from its headquarters in Thousand Oaks, California. The company is at the forefront of employing cutting-edge technology and human genetic data to drive scientific advancements and improve patient outcomes. Amgen remains committed to developing its extensive pipeline of treatments for various conditions including cancer, inflammatory diseases, and obesity, alongside other challenges in healthcare. This commitment to R&D reiterates the company's long-standing reputation for innovation coupled with a strong workplace culture, earning accolades from top publications such as Fast Company and Forbes.

Looking Ahead

Amgen’s recent investment in its U.S. facilities signals a robust future not only for the company but also for the broader biomanufacturing landscape in the U.S. As it enhances its manufacturing capabilities, Amgen fortifies its supply chain resilience while ensuring that patients continue to receive vital treatments without interruption. With an eye on future advancements, the company is well-positioned to tackle health challenges head-on, continuing a legacy of commitment to both innovation and American industry.

• ---

For more information on Amgen, visit their website and follow them on social media platforms like LinkedIn, Instagram, and Twitter.